Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.72 |
| ▸ | CYP2E1 | P05181 | 10/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 10/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 10/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.60 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.58 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | FPR2 | P25090 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209292 | 0.94 | HDAC1 (0.63) | HDAC1CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL14424240 | 0.89 | HDAC1 (0.75) | HDAC1CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL2733630 | 0.85 | HDAC1 (0.82) | HDAC1CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL211177 | 0.78 | HDAC1 (0.71) | HDAC1CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL1065501 | 0.77 | HDAC1 (0.87) | HDAC1CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL8347912 | 0.77 | HDAC1 (0.62) | HDAC1CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL1064755 | 0.77 | CYP2E1 (0.82) | HDAC1CYP2E1CYP2C8CYP2D6CYP2C9 | |
| Bromide SCHEMBL1064752 | 0.76 | CYP2E1 (0.80) | HDAC1CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL2734131 | 0.76 | CYP2E1 (1.00) | HDAC1CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL210720 | 0.75 | HDAC1 (0.79) | HDAC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885CYP2E1 4419/4885CYP2C8 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.